Rosa Miquel-Rodríguez, Beatriz González-Toledo, María-Vanessa Pérez-Gómez, María Ángeles Cobo-Caso, Patricia Delgado-Mallén, Sara Estupiñán, Coriolano Cruz-Perera, Laura Díaz-Martín, Federico González-Rinne, Alejandra González-Delgado, Armando Torres, Flavio Gaspari, Domingo Hernández-Marrero, Alberto Ortiz, Esteban Porrini, Sergio Luis-Lima
Autosomal polycystic kidney disease (ADPKD) is the most common genetic form of kidney failure, reflecting unmet needs in management. Prescription of the only approved treatment (tolvaptan) is limited to persons with rapidly progressing ADPKD. Rapid progression may be diagnosed by assessing glomerular filtration rate (GFR) decline, usually estimated (eGFR) from equations based on serum creatinine (eGFRcr) or cystatin-C (eGFRcys). We have assessed the concordance between eGFR decline and identification of rapid progression (rapid eGFR loss), and measured GFR (mGFR) declines (rapid mGFR loss) using iohexol clearance in 140 adults with ADPKD with ≥3 mGFR and eGFRcr assessments, of which 97 also had eGFRcys assessments...
May 5, 2024: International Journal of Molecular Sciences